Advertisement

Rivaroxaban in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention in Clinical Practice

Published:December 06, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.11.009
      Little is known about the efficacy and safety of rivaroxaban in patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI) in clinical practice. We therefore conducted a prospective observational study to determine the rate of ischemic, embolic, and bleeding events in patients with AF and PCI treated with rivaroxaban in a real-world experience. The RIVA-PCI (“rivaroxaban in patients with AF who underwent PCI”) (clinicaltrials.gov NCT03315650) is a prospective, noninterventional, multicenter study with a follow-up until 14 months, including patients with AF who underwent PCI discharged with rivaroxaban. Between January 2018 and March 2020, 700 patients with PCI treated with rivaroxaban (elective in 50.1%, non-ST-elevation acute coronary syndrome 43.0%, ST-elevation myocardial infarction in 6.9%) were enrolled at 51 German hospitals. After PCI, a dual antithrombotic therapy consisting of rivaroxaban and a P2Y12 inhibitor was administered in 70.7% and triple antithrombotic therapy in 27.9%, respectively. Follow-up information could be obtained in 695 patients (99.3%). Rivaroxaban has been stopped prematurely in 21.6% of patients. Clinical events under rivaroxaban during the 14-month follow-up compared with those observed in the PIONEER-AF PCI trial included cardiovascular death (2.0% % vs 2.0%), myocardial infarction (0.9% vs 3.0%), stent thrombosis (0.2% vs 0.8%), stroke (1.3% vs 1.3%), International Society on Thrombosis and Haemostasis major (4.2% vs 3.9%), and International Society on Thrombosis and Haemostasis nonmajor clinically relevant bleeding (15.3% vs 12.9%). Therefore, in this real-world experience, rivaroxaban in patients with AF who underwent PCI is associated with ischemic and bleeding event rates comparable with those observed in the randomized PIONEER-AF PCI trial.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zeymer U
        • Annemans L
        • Danchin N
        • Pocock S
        • Newsome S
        • Van de Werf F
        • Medina J
        • Bueno H.
        Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry.
        Eur Heart J Acute Cardiovasc Care. 2019; : 121-129
        • Duerschmied D
        • Brachmann J
        • Darius H
        • Frey N
        • Katus HA
        • Rottbauer W
        • Schäfer A
        • Thiele H
        • Bode C
        • Zeymer U.
        Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?.
        Clin Res Cardiol. 2018; 107: 533-538
        • Kirchhof P
        • Benussi S
        • Kotecha D
        • Ahlsson A
        • Atar D
        • Casadei B
        • Castella M
        • Diener HC
        • Heidbuchel H
        • Hendriks J
        • Hindricks G
        • Manolis AS
        • Oldgren J
        • Popescu BA
        • Schotten U
        • Van Putte B
        • Vardas P
        • ESC Scientific Document Group
        2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962
        • Schömig A
        • Neumann FJ
        • Kastrati A
        • Schühlen H
        • Blasini R
        • Hadamitzky M
        • Walter H
        • Zitzmann-Roth EM
        • Richardt G
        • Alt E
        • Schmitt C
        • Ulm K.
        A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
        N Engl J Med. 1996; 334: 1084-1089
        • Lip GY
        • Windecker S
        • Huber K
        • Kirchhof P
        • Marin F
        • JM Ten Berg
        • Haeusler KG
        • Boriani G
        • Capodanno D
        • Gilard M
        • Zeymer U
        • Lane D
        • Reviewers Document
        • Storey RF
        • Bueno H
        • Collet JP
        • Fauchier L
        • Halvorsen S
        • Lettino M
        • Morais J
        • Mueller C
        • Potpara TS
        • Rasmussen LH
        • Rubboli A
        • Tamargo J
        • Valgimigli M
        • Zamorano JL
        Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endor sed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS).
        Eur Heart J. 2014; 35: 3155-3179
        • Dewilde WJ
        • Oirbans T
        • Verheugt FW
        • Kelder JC
        • De Smet BJ
        • Herrman JP
        • Adriaenssens T
        • Vrolix M
        • Heestermans AA
        • Vis MM
        • Tijsen JG
        • van ’t Hof AW
        • ten Berg JM
        • van
        • WOEST study investigators
        Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
        Lancet. 2013; 38: 1107-1115
        • Gibson CM
        • Mehran R
        • Bode C
        • Halperin J
        • Verheugt FW
        • Wildgoose P
        • Birmingham M
        • Ianus J
        • Burton P
        • van Eickels M
        • Korjian S
        • Daaboul Y
        • Lip GY
        • Cohen M
        • Husted S
        • Peterson ED
        • Fox KA.
        Prevention of bleeding in patients with atrial fibrillation undergoing PCI.
        N Engl J Med. 2016; 375: 2423-2434
        • Cannon CP
        • Bhatt DL
        • Oldgren J
        • Lip GYH
        • Ellis SG
        • Kimura T
        • Maeng M
        • Merkely B
        • Zeymer U
        • Gropper S
        • Nordaby M
        • Kleine E
        • Harper R
        • Manassie J
        • Januzzi JL
        • Ten Berg JM
        • Steg PG
        • Hohnloser SH
        RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation.
        N Engl J Med. 2017; 377: 1513-1524
        • Lopes RD
        • Heizer G
        • Aronson R
        • Vora AN
        • Massaro T
        • Mehran R
        • Goodman SG
        • Windecker S
        • Darius H
        • Li J
        • Averkov O
        • Bahit MC
        • Berwanger O
        • Budaj A
        • Hijazi Z
        • Parkhomenko A
        • Sinnaeve P
        • Storey RF
        • Thiele H
        • Vinereanu D
        • Granger CB
        • Alexander JH
        • AUGUSTUS Investigators
        Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation.
        N Engl J Med. 2019; 380: 1509-1524
        • Vranckx P
        • Valgimigli M
        • Eckardt L
        • Tijssen J
        • Lewalter T
        • Gargiulo G
        • Batushkin V
        • Campo G
        • Lysak Z
        • Vakaliuk I
        • Milewski K
        • Laeis P
        • Reimitz PE
        • Smolnik R
        • Zierhut W
        • Goette A.
        Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
        Lancet. 2019; 394: 1335-1343
        • Collet JP
        • Thiele H
        • Barbato E
        • Barthélémy O
        • Bauersachs J
        • Bhatt DL
        • Dendale P
        • Dorobantu M
        • Edvardsen T
        • Folliguet T
        • Gale CP
        • Gilard M
        • Jobs A
        • Jüni P
        • Lambrinou E
        • Lewis BS
        • Mehilli J
        • Meliga E
        • Merkely B
        • Mueller C
        • Roffi M
        • Rutten FH
        • Sibbing D
        • Siontis GCM
        • ESC Scientific Document Group
        2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
        Eur Heart J. 2021; 42: 1289-1367
      1. Zeymer U, Toelg R, Wienbergen H, Hobbach HP, Cuneo A, Bekeredjian R, Ritter O, Hailer B, Hertting K, Hennersdorf M, Scholtz W, Lanzer P, Mudra H, Schwefer M, Schwimmbeck PL, Liebetrau C, Thiele H, Claas C, Riemer T, Zahn R. Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany [published online March 3, 2022]. Herz doi: 10.1007/s00059-022-05099-6.

        • Cutlip DE
        • Windecker S
        • Mehran R
        • Boam A
        • Cohen DJ
        • van Es GA
        • Steg PG
        • Morel MA
        • Mauri L
        • Vranckx P
        • McFadden E
        • Lansky A
        • Hamon M
        • Krucoff MW
        • Serruys PW
        Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Thygesen K
        • Alpert JS
        • Jaffe AS
        • Chaitman BR
        • Bax JJ
        • Morrow DA
        • White HD
        • ESC Scientific Document Group
        Fourth universal definition of myocardial infarction (2018).
        Eur Heart J. 2019; 40: 237-269
        • Schulman S
        • Kearon C
        Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J Thromb Haemost. 2005; 3: 692-694
        • Mehran R
        • Rao SV
        • Bhatt DL
        • Gibson CM
        • Caixeta A
        • Eikelboom J
        • Kaul S
        • Wiviott SD
        • Menon V
        • Nikolsky E
        • Serebruany V
        • Valgimigli M
        • Vranckx P
        • Taggart D
        • Sabik JF
        • Cutlip DE
        • Krucoff MW
        • Ohman EM
        • Steg PG
        • White H.
        Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
        Circulation. 2011; 123: 2736-2747
        • Valgimigli M
        • Bueno H
        • Byrne RA
        • Collet JP
        • Costa F
        • Jeppsson A
        • Jüni P
        • Kastrati A
        • Kolh P
        • Mauri L
        • Montalescot G
        • Neumann FJ
        • Petricevic M
        • Roffi M
        • Steg PG
        • Windecker S
        • Zamorano JL
        • Levine GN
        • ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies
        2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
        Eur Heart J. 2018; 39: 213-260
        • Neumann FJ
        • Sousa-Uva M
        • Ahlsson A
        • Alfonso F
        • Banning AP
        • Benedetto U
        • Byrne RA
        • Collet JP
        • Falk V
        • Head SJ
        • Jüni P
        • Kastrati A
        • Koller A
        • Kristensen SD
        • Niebauer J
        • Richter DJ
        • Seferovic PM
        • Sibbing D
        • Stefanini GG
        • Windecker S
        • Yadav R
        • Zembala MO
        • ESC Scientific Document Group
        2019 ESC/EACTS Guidelines on myocardial revascularization.
        Eur Heart J. 2018; 40: 87-165
        • Lopes RD
        • Leonardi S
        • Wojdyla DM
        • Vora AN
        • Thomas L
        • Storey RF
        • Vinereanu D
        • Granger CB
        • Goodman SG
        • Aronson R
        • Windecker S
        • Thiele H
        • Valgimigli M
        • Mehran R
        • Alexander JH.
        Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial.
        Circulation. 2020; 141: 781-783
        • Casula M
        • Fortuni F
        • Ferlini M
        • Fabris F
        • Oltrona Visconti L
        • Leonardi S
        Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus clopidogrel in Patients with atrial fibrillation Undergoing Percutaneous Coronary Intervention.
        Am J Cardiovasc Drugs. 2021; 21: 231-240
        • Wilke T
        • Groth A
        • Fuchs A
        • Pfannkuche M
        • Maywald U.
        Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large sample of 38,076 German patients.
        Eur J Clin Pharmacol. 2017; 73: 1437-1447
        • Paquette M
        • Riou França L
        • Teutsch C
        • Diener HC
        • Lu S
        • Dubner SJ
        • Ma CS
        • Rothman KJ
        • Zint K
        • Halperin JL
        • Huisman MV
        • Lip GYH
        • Nieuwlaat R.
        Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation.
        J Am Coll Cardiol. 2017; 70: 1573-1583
        • Verdecchia P
        • D'Onofrio A
        • Russo V
        • Fedele F
        • Adamo F
        • Benedetti G
        • Ferrante F
        • Lodigiani C
        • Paciullo F
        • Aita A
        • Bartolini C
        • Molini MG
        • Di Lenarda A
        • Mazzone C
        • Scotti L
        • Lanati EP
        • Iorio A
        Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study.
        J Cardiovasc Med (Hagerstown). 2019; 20: 66-73
        • Bai L
        • Yang XH
        • Zhou YQ
        • Cui XR
        • Fu LZ
        • Zhang JD.
        Safety and efficacy evaluation of antithrombotic therapy with rivaroxaban and clopidogrel after PCI in Chinese patients.
        Clin Appl Thromb Hemost. 2022; 2810760296221074681